EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-Lasting, Fine-Tuned Anti-Tumor Activity of Recombinant Listeria monocytogenes Vaccine Is Controlled by Pyroptosis and Necroptosis Regulatory and Effector Molecules

Abolaji S Olagunju, Andrew V D Sardinha, Gustavo P Amarante-Mendes iD

Pathogens · 25.09.2024 · 13 (10) · 828

DOI: 10.3390/pathogens13100828 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, online erschienen am 25.09.2024. Verfasst von Abolaji S Olagunju und 2 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Imunologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo 05508-000, SP, Brazil. Hauptthemen laut MEDLINE: Pyroptosis, Listeria monocytogenes, CD8-Positive T-Lymphocytes, Cancer Vaccines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, National Council for Scientific and Technological Development, FAPESP.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

One of the main objectives of developing new anti-cancer vaccine strategies is to effectively induce CD8+ T cell-mediated anti-tumor immunity. Live recombinant vectors, notably Listeria monocytogenes, have been shown to elicit a robust in vivo CD8+ T-cell response in preclinical settings. Significantly, it has been demonstrated that Listeria induces inflammatory/immunogenic cell death mechanisms such as pyroptosis and necroptosis in immune cells that favorably control immunological responses. Therefore, we postulated that the host’s response to Listeria-based vectors and the subsequent induction of CD8+ T cell-mediated immunity would be compromised by the lack of regulatory or effector molecules involved in pyroptosis or necroptosis. To test our hypothesis, we used recombinant L. monocytogenes carrying the ovalbumin gene (LM.OVA) to vaccinate wild-type (WT), caspase-1/11−/−, gsdmd−/−, ripk3−/−, and mlkl−/− C57Bl/6 mice. We performed an in vivo cytotoxicity assay to assess the efficacy of OVA-specific CD8+ T lymphocytes in eliminating target cells in wild-type and genetically deficient backgrounds. Furthermore, we evaluated the specific anti-tumor immune response in mice inoculated with the B16F0 and B16F0.OVA melanoma cell lines. Our findings demonstrated that while caspase-1/11 and GSDMD deficiencies interfere with the rapid control of LM.OVA infection, neither of the KOs seems to contribute to the early activation of OVA-specific CTL responses. In contrast, the individual deficiency of each one of these proteins positively impacts the generation of long-lasting effector CD8+ T cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyroptosisListeria monocytogenesCD8-Positive T-LymphocytesCancer VaccinesNecroptosisMice, Inbred C57BLPhosphate-Binding ProteinsMice, KnockoutOvalbuminAnimalsMiceIntracellular Signaling Peptides and ProteinsVaccines, SyntheticReceptor-Interacting Protein Serine-Threonine KinasesCaspase 1Caspases, InitiatorProtein KinasesCell Line, TumorMelanoma, ExperimentalGasdermins

Stichwörter der Autor:innen

CD8 T cellL. monocytogenesanti-tumor vaccinenecroptosispyroptosis

Substanzen

Cancer VaccinesPhosphate-Binding ProteinsOvalbuminIntracellular Signaling Peptides and ProteinsVaccines, SyntheticGsdmd protein, mouseReceptor-Interacting Protein Serine-Threonine KinasesCaspase 1Casp4 protein, mouseCaspases, Initiator

Autor:innen und Institutionen

  • Departamento de Imunologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo 05508-000, SP, Brazil.
  • Instituto de Investigação em Imunologia, Instituto Nacional de Ciência e Tecnologia (INCT-iii), São Paulo 05508-000, SP, Brazil.

ORCID-Profile: Gustavo P Amarante-Mendes

Förderung

  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • National Council for Scientific and Technological Development
  • FAPESP
  • CNPq

Zitieren

APA

Olagunju, A. S., Sardinha, A. V. D., & Amarante-Mendes, G. P. (2024). Long-Lasting, Fine-Tuned Anti-Tumor Activity of Recombinant Listeria monocytogenes Vaccine Is Controlled by Pyroptosis and Necroptosis Regulatory and Effector Molecules. Pathogens, 13(10), 828. https://doi.org/10.3390/pathogens13100828

Vancouver

Olagunju AS, Sardinha AVD, Amarante-Mendes GP. Long-Lasting, Fine-Tuned Anti-Tumor Activity of Recombinant Listeria monocytogenes Vaccine Is Controlled by Pyroptosis and Necroptosis Regulatory and Effector Molecules. Pathogens. 2024;13(10):828. doi:10.3390/pathogens13100828

BibTeX
@article{Olagunju2024,
  author = {Olagunju, Abolaji S and Sardinha, Andrew V D and Amarante-Mendes, Gustavo P},
  title = {Long-Lasting, Fine-Tuned Anti-Tumor Activity of Recombinant Listeria monocytogenes Vaccine Is Controlled by Pyroptosis and Necroptosis Regulatory and Effector Molecules},
  journal = {Pathogens},
  year = {2024},
  volume = {13},
  number = {10},
  pages = {828},
  doi = {10.3390/pathogens13100828}
}
Kostenlos starten →